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AbstrACt
Purpose The Predictors of Breast Cancer Recurrence 
(ProBe CaRe) study was established to evaluate 
modification of tamoxifen (TAM) effectiveness in 
premenopausal women through reduced activity of TAM-
metabolising enzymes. It comprehensively evaluates the 
effects of pharmacogenetic variants, use of concomitant 
medications and biomarkers involved in oestrogen 
metabolism on breast cancer recurrence risk.
Participants The ProBe CaRe study was established 
using resources from the Danish Breast Cancer Group 
(DBCG), including 5959 premenopausal women diagnosed 
with stage I–III primary breast cancer between 2002 and 
2010 in Denmark. Eligible participants were divided into 
two groups based on oestrogen receptor alpha (ERα) 
expression and receipt of TAM therapy, 4600 are classified 
as ERα+/TAM+ and 1359 are classified as ERα−/TAM−. 
The ProBe CaRe study is a population-based cohort study 
nested in a nearly complete source population, clinical, 
tumour and demographic data were abstracted from 
DBCG registry data. Linkage to Danish registries allows for 
abstraction of information regarding comorbid conditions, 
comedication use and mortality. Formalin-fixed paraffin-
embedded tissue samples have been prepared for DNA 
extraction and immunohistochemical assay.
Findings to date To mitigate incorrect classification of 
patients into specific categories, we conducted a validation 
substudy. We compared data acquired from registry and 
from medical record review to calculate positive predictive 
values (PPVs) and negative predictive values. We observed 
PPVs near 100% for tumour size, lymph node involvement, 
receptor status, surgery type, receipt of radiotherapy, 
receipt of chemotherapy and TAM treatment. We found that 
the PPVs were 96% (95% CI 83% to 100%) for change 
in endocrine therapy and 61% (95% CI 42% to 77%) for 
menopausal transition.
Future plans The ProBeCaRe cohort study is well 
positioned to comprehensively examine pharmacogenetic 
variants. We will use a Bayesian pathway analysis to 
evaluate the complete TAM metabolic path to allow for 
gene–gene interactions, incorporating information of other 
important patient characteristics.
IntroduCtIon 
Endocrine therapy improves survival in 
patients with breast cancer regardless of 
axillary lymph node status.1 The Predictors 
of Breast Cancer Recurrence (ProBe CaRE) 
cohort study was established to evaluate modi-
fication of tamoxifen (TAM) effectiveness in 
premenopausal women through reduced 
activity of TAM-metabolising enzymes. Candi-
dates for adjuvant TAM therapy include 
patients with stage I–IV breast cancer with 
oestrogen receptor (ER) positive tumours, 
who constitute about two-thirds2 of the 
approximately 1.7 million newly diagnosed 
patients with breast cancer each year world-
wide.3 Current guidelines recommend that 
premenopausal patients with ER alpha posi-
tive (ERα+) cancers receive TAM for 5–10 
years,4–6 which reduces recurrence risk by 
nearly half,6 and that TAM may be offered to 
postmenopausal women with ERα+ cancers 
as an alternative to aromatase inhibitors. 
TAM metabolism is complex, but is princi-
pally catalysed by cytochrome P450 enzymes. 
Some metabolites bind with the ER with 
significantly greater affinity than TAM itself, 
especially endoxifen, which has the highest 
strengths and limitations of this study
 ► One potential limitation of the Predictors of Breast 
Cancer Recurrence study is the homogeneity of the 
study sample, as almost all are of European descent.
 ► In addition to being the first large epidemiological 
study to examine reduced activity of tamoxifen me-
tabolism in premenopausal women, this study is 
strengthened by completeness of high-quality data.
 ► Our study includes a validation substudy to mitigate 
errors from the  incorrect classification of patients 
into specific categories of key analytical variables.
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ER-binding activity among TAM metabolites. Activity 
of the enzymes involved in TAM metabolism can vary 
between individuals due to inherited gene variants7–11 
or use of comedications.7 8 Although many studies have 
explored the association between these gene variants or 
use of comedications and failure of TAM treatment,12 13 
which manifests clinically as a recurrence, the interpre-
tation of these studies remains controversial. Current 
clinical guidelines do not recommend genotyping these 
variant alleles to support treatment decisions,1 5 14 but 
do recommend avoiding inhibiting comedications.15 
To date, little available evidence on this topic is specific 
to premenopausal patients with breast cancer. The 
competition between oestrogen and TAM for ER binding 
is highly important for these patients because TAM is a 
first-line guideline-recommended therapy1 5 for premeno-
pausal patients and because premenopausal women have 
higher concentrations of oestrogens to compete with 
TAM for ER binding. Oestradiol (E2), the most active 
oestrogen metabolite, binds with the ER with approxi-
mately the same affinity as endoxifen.16 Premenopausal 
women have 10-fold higher concentrations of E2 than 
postmenopausal women17 and E2 concentrations tend 
to increase during TAM therapy.17 18 This suggests that 
inhibition of TAM-metabolising enzymes is more likely to 
decrease effectiveness in premenopausal women, yet they 
have been seldom studied in this topic area.
research questions
We established a premenopausal cohort of patients with 
breast cancer to fill this important evidence gap, with the 
following primary study aims:
Assess pharmacogenetics of TAM metabolism and risk of breast 
cancer recurrence
We will assess the pharmacogenetics of TAM metabolism 
by genotyping 32 variants in 15 enzymes (table 1) thought 
to affect the concentration of the most active TAM metab-
olites, and will evaluate the association between these 
variants and breast cancer recurrence in TAM-treated 
premenopausal patients with breast cancer. Each of the 
selected enzymes is involved in at least one step in the 
TAM metabolic pathway (figure 1). Interactions with 
comedications that inhibit these metabolic enzymes also 
will be evaluated.
Assess the interaction between the pharmacogenetics of TAM 
metabolism and ER beta (ERβ) expression
We will assess the effect of interaction between the phar-
macogenetics of TAM metabolism and ERβ expression 
on risk of breast cancer recurrence. Previous studies 
have shown that coexpression of ERβ is associated with 
improved survival among patients with ERα+ tumours who 
are treated with TAM.19 20 The ERβ receptor opposes 
ERα-mediated proliferation.19 Tumours that express 
Table 1 Selected functional variants and inhibitor comedications in genes whose enzymes metabolise tamoxifen
Gene
No of selected 
functional variants SNPs Inhibitor comedications
CYP2D6 5 rs1065852, rs16947, 
rs3892097, rs28371706, 
rs28371725
Bupropion, cinacalcet, fluoxetine, paroxetine, quinidine, 
duloxetine, sertraline, terbinafine, amiodarone, cimetidine, 
indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, 
ketoconazole, nefazodone, saquinavir, telithromycin, 
aprepitant, erythromycin, Fluconazole, verapamil, diltiazem, 
cimetidine, voriconazole
CYP3A 1 rs10273424
CYP3A5 1 rs776746
CYP2C9 2 rs1057910, rs1799853 Fluconazole, amiodarone, voriconazole
CYP2C19 2 rs12248560, rs4244285
CYP2B6 2 rs3745274, rs8192709
CYP1A1 1 rs1048943
SULT1A1 3 rs1042157, rs1801030, 
rs9282861
SULT1E1 2 rs3775775, rs3775778
UGT2B7 1 rs7434332
UGT2B10 1 rs294769
ABCC2 3 rs3740065, rs717620, 
rs8187710
ABCG2 3 rs1564481, rs2231164, 
rs2622604
ABCB1 4 rs10248420, rs1045642, 
rs1128503, rs2032582
UGT2B15 1 rs1902023
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both ERα and ERβ are less aggressive than tumours that 
express homodimers of ERα,19 21 due to the attenuated 
stimulation response from ERα/ERβ heterodimers. This 
suggests that metabolic inhibition may only affect ERβ− 
tumours. In vitro, analyses have demonstrated that in 
ERα+/ERβ+MCF7 cells, proliferation is inhibited by a 
wide range of endoxifen concentrations.22 Still, in ERα+/
ERβ– MCF7 cells, only physiologically high endoxifen 
concentrations inhibit proliferation,22 indicating that 
metabolic inhibition affects risk of recurrence only when 
ERβ is absent.
Assess interaction between inhibition of TAM metabolism and 
oestrogen-regulating enzymes
Finally, we will assess the association between tumour 
expression of 17β-hydroxysteroid dehydrogenase 1 and 
2 (17βHSD1 and 17βHSD2) and breast cancer recur-
rence. 17βHSD1 catalyses the conversion of oestrone to 
the most potent form of oestrogen, E2 and 17βHSD2 
catalyses the reverse reaction.23 E2 has the highest 
binding affinity for ER, and endoxifen acts through 
competitive inhibition at the receptor-binding site.23 In 
breast tumour tissue, 17βHSD1 is more highly expressed 
than 17βHSD2. The opposite is usually observed in adja-
cent normal tissue.24 Tumours with higher capacity to 
produce E2 endogenously through increased expression 
of the 17βHSD1 enzyme are more likely to overwhelm 
the TAM metabolites in competition for ER binding, 
affecting TAM effectiveness. These enzymes are ideal 
therapeutic targets to modulate E2 concentrations in 
tumour cells, and candidate inhibitors have been devel-
oped.23 25 We will evaluate whether disequilibrium of the 
17βHSD1 and −2 enzymes (ratio >1) results in compro-
mised TAM effectiveness.
Cohort desCrIPtIon
The ProBe CaRe cohort was established using the 
resources of the Danish Breast Cancer Group (DBCG) 
registry. The DBCG registry was established in 1976 
and began to register patients in 1977, with the goals 
of standardising treatment, facilitating clinical trials 
and monitoring outcomes among Danish patients with 
breast cancer.26 Since its inception, the DBCG has regis-
tered over 90% of women diagnosed with breast cancer 
in Denmark. Patients with breast cancer are registered 
in the DBCG via standardised forms. The registry has 
a standard protocol to collect information on tumour, 
treatment and patient characteristics. Using this infor-
mation-rich resource, the ProBe CaRe cohort is nested in 
a nearly complete source population of premenopausal 
women diagnosed with stage I–III first primary breast 
cancer between 2002 and 2010 whose breast cancer was 
reported to the DBCG. In Denmark, all citizens and legal 
residents are assigned a Civil Personal Register (CPR) 
number, a unique 10-digit personal identifier assigned 
at birth or on immigration that is used for identification 
across all national registries electronic online supplemen-
tary figure 1.27
Of the 8047 premenopausal women diagnosed with 
breast cancer between 2002 and 2010 and recorded in the 
DBCG registry, 5959 cancers were identified as eligible 
based on being a stage I–III first primary breast cancer 
and untreated with neoadjuvant therapy; all others 
(n=2088) were excluded. The 5959 eligible patients then 
were divided into two cohorts based on ERα expres-
sion and receipt of TAM therapy (figure 2). To address 
competing explanations (eg, if the biomarkers under 
study affect risk directly rather than mediating the TAM 
effect), we will also evaluate the risk of recurrence in the 
Figure 1 Metabolic pathway of tamoxifen and related metabolites including enzymes that have been 
genotyped. ER, oestrogen receptor.
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subset of women with ERα− tumours who did not receive 
TAM therapy (T−).
Our final ProBe CaRe study population consists of these 
5959 patients with breast cancer divided into a cohort 
of ERα+/T+ (4600 patients) and a cohort of ERα−/
T− (1359 patients). The sociodemographic and clinical 
characteristics of the two cohorts are described in table 2. 
The distribution of the clinical and demographic charac-
teristics between the two cohorts (ERα+/T+ vs ERα−/T–) 
are relatively similar. They only differ meaningfully with 
respect to progesterone receptor (PR) status (58% vs 
1.4% PR+, respectively) and human epidermal growth 
factor receptor 2 (HER2) status (14% vs 26% HER2+, 
respectively). With respect to outcomes, the ER−/TAM− 
cohort has a higher proportion of subjects who experi-
enced recurrence (8.6% vs 16%, respectively) and who 
died by the end of follow-up (7.8% vs 18%, respectively). 
This pattern is to be expected, as ER− breast cancers 
generally have a worse prognosis than ER+ cancers, espe-
cially within the first 5 years following diagnosis.28 29
Cohort follow-up
Women diagnosed with breast cancer and subsequently 
enrolled in the DBCG registry undergo semiannual 
examinations during the first 5 years after diagnosis and 
annual examinations during years 6–10.30 Women under-
going treatment for breast cancer receive endocrine 
therapy through the Danish government and obtain their 
medicine at the hospital, which will be used to estimate 
TAM adherence. Members of both the ERα+/T+ and the 
ERα−/T− ProBe CaRe cohorts have been followed from 
breast cancer diagnosis to the first of (1) recurrence, (2) 
death, (3) 10 years of follow-up, (4) loss to follow-up due 
to emigration, (5) another malignancy or (6) the end 
of the study follow-up period. Breast cancer recurrence 
was identified using the DBCG registry. We adopted the 
DBCG definition of breast cancer recurrence as any 
type of breast cancer diagnosed subsequent to the initial 
course of therapy.30 Recurrences are then further cate-
gorised as locoregional (in the scar or regional lymph 
nodes), contralateral (opposite breast), distant (all other 
sites) or unknown (site of recurrence not documented). 
The date of recurrence is recorded in the DBCG registry, 
including recurrences diagnosed between scheduled 
follow-up exams. Mortality and emigration were identi-
fied using the Danish Civil Registration System, which is 
updated daily.27 Emigration is the only expected source 
of loss to follow-up and has impacted less than 1% of the 
study population.
data collection
Registry data
Once participants eligible for ProBe CaRe were selected 
from the DBCG registry, we extracted clinical and 
Figure 2 Selection of study sample and group based on the inclusion criteria. The source population consisted of 8047 
premenopausal women diagnosed with a first primary stage I–III breast cancer and reported to the Danish Breast Cancer 
Group between 2002 and 2010. After exclusions (n=2088), the study population consists of 5959 patients in the ProBe 
CaRe study. ER, oestrogen receptor; ERα, oestrogen receptor alpha; ProBe CaRe, Predictors of Breast Cancer Recurrence; 
TAM, tamoxifen therapy. 
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demographic information from the DBCG registry. 
This information included date and place of diagnosis, 
tumour characteristics, treatment received and patient 
characteristics, which are presented in electronic 
online supplementary table 1. We also extracted infor-
mation on comorbid diseases at time of breast cancer 
diagnosis, summarised using the Charlson Comorbidity 
Index.31 32 The registry information allows us to update 
Table 2 Distribution of clinical and tumour characteristics 
by ER status and receipt of tamoxifen among the 5959 
participants in a population-based cohort of premenopausal 
women diagnosed with first primary breast cancer, ProBe 
CaRe study
Patient and tumour 
characteristics
ER+/TAM+ ER−/TAM−
N % N %
Total 4600 100 1359 100
Age at diagnosis
  <35 222 4.8 182 23
  35–39 487 11 229 27
  40–44 1123 24 321 24
  45–49 1668 36 385 28
  50+ 1100 24 242 18
Menopausal status at diagnosis
  Premenopausal 4600 100 1359 100
Stage at diagnosis
  Stage I 1184 26 402 29.6
  Stage II 2476 54 702 51.7
  Stage III 917 20 246 18.1
  Unknown stage 23 0.5 9 0.7
Tumour size
  <2 mm 2646 58 677 50
  2≤5 mm 1780 39 632 47
  >5 mm 156 3.4 44 3.2
  Unknown 18 0.4 6 0.4
No of metastatic lymph nodes
  0 1704 37 695 51
  1 1148 25 238 17
  2 583 13 116 9
  3+ 1152 25 306 23
  Unknown 13 0.3 4 0.3
Lymph node evaluation
  No 8 0.2 3 0.2
  Yes 4592 100 1356 100
Histological grade
  Unsuitable 10 0.2 13 1
  I 955 21 21 1.5
  II 2391 52 216 16
  III 950 21 884 65
  Unknown 294 6.4 225 17
Type of primary surgery
  Mastectomy 2033 44 627 46
  Lumpectomy 2567 56 732 54
Progesterone receptor status
  PR− 383 8.3 1121 83
  PR+ 2680 58 19 1.4
  Unknown/not measured 1537 33 219 16
Continued
Patient and tumour 
characteristics
ER+/TAM+ ER−/TAM−
N % N %
HER2 status
  HER2− 2887.00 63 692 51
  HER2+ 619 14 354 26
  Unknown/not measured 1094 24 313 23
Intention to treat with chemotherapy
  No 144 3 14 1
  Yes 4456 97 1345 99
Chemotherapy
  No 437 9 109 8
  Yes 4163 91 1250 92
Intention to treat with tamoxifen
  No 70 1.5 1351 99
  Yes 4530 98 8 0.6
Radiation therapy
  No 655 14 267 20
  Yes 3945 86 1092 80
Anti-HER2 therapy
  No 2887 63 692 51
  Yes 619 13 354 26
  Unknown 1094 24 313 23
Recurrence
  No 4204 91 1143 84
  Yes 396 8.6 216 16
Another malignancy
  No 4544 99 1341 99
  Yes 56 1.2 18 1.3
Dead at end of follow-up
  No 4239 92 1115 82
  Yes 361 8 244 18
Charlson Comorbidity Score
  0 4587 99 1344 99
  1 4 0.1 4 0.3
  2 2 0 3 0.2
  3+ 7 0.2 8 0.6
ER, oestrogen receptor; HER, human epidermal growth factor 
receptor 2; ProBe CaRe, Predictors of Breast Cancer Recurrence; 
PR, progesterone receptor; TAM, tamoxifen therapy.
Table 2 Continued 
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the participants’ conditions during study follow-up and 
therefore to account for time-varying exposures and 
confounding factors. The CPR number for each patient 
was used to link cohort members to the Danish National 
Prescription Registry,33 which provided information on 
filled prescriptions of drugs that inhibit TAM-metab-
olising enzymes. This allowed us to assess the drug–drug 
interactions discussed above.
Biobank
The CPR number for each patient was used to identify 
the hospital at which the surgery was performed and to 
locate and retrieve the corresponding formalin-fixed 
paraffin-embedded (FFPE) tissue samples. The list of 
ProBe CaRe cohort members and their CPR numbers 
and hospitals of diagnosis were provided to a medical 
research technician at the Institute of Pathology, blinded 
to whether the CPR numbers corresponded to a patient 
with a recurrence. The technician reviewed a description 
of the available tissue blocks (routinely available in the 
Danish pathology registry34), identified the tumour-rich 
and non-neoplastic blocks for each patient, and specified 
which FFPE blocks should be requested from the hospi-
tals. This list of blocks to be requested was then returned 
to the Department of Clinical Epidemiology, which 
prepared and mailed the request letters to the pathology 
archives at the respective Danish hospitals. Staff at the 
hospital pathology archives returned the blocks to the 
Department of Clinical Epidemiology, which assigned 
a project identification number to the block and then 
provided it to the Institute of Pathology. The project 
identification number maintained blinding of laboratory 
personnel to whether blocks corresponded to patients 
with a recurrence. The Department of Clinical Epide-
miology maintains the key linking the project identifica-
tion number for the blocks to the clinical data, including 
recurrence status.
Non-neoplastic tissue samples are taken routinely 
from normal adjacent tissue or cancer-free lymph nodes 
resected during breast cancer surgery and were used as 
controls in creation of tissue microarrays (TMAs). Of 
the 4600 patients included in the ERα+/T+ cohort, 4599 
patients had samples evaluated by clinicians, and tumour 
samples were available for 3959 (86%). Among the ER−/
TAM− cohort, 1139 (84%) patients had tumour samples 
available. Distribution of clinical and demographic char-
acteristics among patients with and without, available 
tumour samples are described in table 3. Of patients 
included in the ERα+/T+ cohort, 2746 (82%) had a 
non-neoplastic tissue sample available, while 1082 (80%) 
patients in the ER−/TAM− cohort had non-neoplastic 
tissue samples available. Distributions of demographic 
and clinical characteristics among patients with and 
without non-neoplastic tissue samples are summarised in 
electronic online supplementary table 2.
Sections of collected tissue blocks have been prepared 
for DNA extraction and immunohistochemical (IHC) 
assay. In accordance with the study’s primary aims, we will 
genotype 32 variants across 15 genes known to be involved 
in TAM metabolism, in order to predict extent of meta-
bolic inhibition. We will also reassay ERα expression to 
ensure correct classification of the two cohorts, as orig-
inal ERα expression was measured in different pathology 
laboratories using different methods. In our previous 
case–control study of postmenopausal patients diagnosed 
during 1985–2001, we reported 95% concordance of 
positive ERα expression between initial assays and reas-
says and 74% concordance of negative ERα expression 
between initial assays and reassays.35 ERβ expression will 
be assayed using IHC in TMAs to assess its possible modi-
fication of TAM metabolic inhibition. Expression of the 
enzymes 17βHSD1 and 17βHSD2 also will be assayed 
using IHC to address the study aim examining whether 
the ratio of these two enzymes modulates TAM’s effi-
cacy in preventing breast cancer recurrence. The afore-
mentioned assays of biomarkers are the primary starting 
point. However, we anticipate that the study will yield a 
substantial tumour biobank and ultimately provide a valu-
able resource to researchers for further characterisation 
of prognostic and predictive biomarkers in premeno-
pausal breast cancer.
Validation substudy
Registry data are not error-free.36 To mitigate incor-
rect classification of patients into specific categories, we 
conducted a validation substudy.37 By comparing data 
procured both from the registry and from medical record 
review, we calculated positive predictive values (PPVs) 
and negative predictive values and their corresponding 
CIs for key analytical variables. We observed near perfect 
PPVs for tumour size, lymph node involvement, receptor 
status, surgery type, receipt of radiotherapy, receipt of 
chemotherapy and TAM treatment. The PPVs were 96% 
(95% CI 83% to 100%) for change in endocrine therapy 
and 61% (95% CI 42% to 77%) for menopausal tran-
sition. While the PPV for DBCG-recorded recurrence 
was 100%, there were more recurrences reported in the 
Table 3 Summary of exposure, covariate and outcome 
variables collected in the ProBe CaRe study
Exposures Outcome
Genetic variants Recurrence
ERα and ERβ Mortality
17βHSD1 and 17βHSD2
Biomarkers
Clinical Demographic
Tumour characteristics Age
Treatment therapy Region
Comorbidity Hospital of diagnosis
Medication history and use
ERα, oestrogen receptor alpha; ERβ, oestrogen receptor 
beta; 17β-hydroxysteroid dehydrogenase 1 and 2; ProBe CaRe, 
Predictors of Breast Cancer Recurrence.
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medical records than reported in the DBCG database.37 
These parameters will allow us to adjust for measurement 
errors in our analyses, improving data quality and confi-
dence in the resulting measures of association.38
Patient and public involvement
Patients and public were not involved in the development 
of this study.
FIndIngs to dAte
In our preceding ProBe CaRe nested case–control study, 
where 94% patients with breast cancer were postmeno-
pausal, we compared rates of breast cancer recurrence for 
women with a polymorphism that impairs the function 
of CYP2D6 (an enzyme involved in TAM metabolism) to 
those in women without this polymorphism and found a 
null association (adjusted OR 0.99; 95% CI 0.76 to 1.3).39 
We further evaluated functional variants in the phase 
II UDP-glucuronosyl transferases, which contributes to 
deactivation TAM, and again found near null associa-
tions.40 We have assessed drug–drug interactions with 
concomitant use of selective serotonin reuptake inhib-
itor antidepressants using the Danish National Prescrip-
tion Registry, and reported an adjusted OR of 1.1 (95% 
CI 0.7 to 1.7).41
The current ProBe CaRe longitudinal cohort will 
build on our previous research to address gene–gene 
and gene–drug interactions that may compromise TAM 
effectiveness by focusing on premenopausal women and 
by more comprehensively evaluating variants in the meta-
bolic path. We will use a Bayesian pathway analysis, (the 
Algorithm for Learning Pathway Structure (ALPS)),42 to 
evaluate the complete TAM metabolic pathway and to 
allow for identification of gene–gene interactions, while 
also estimating the net effect of the entire pathway.43 This 
analytical approach will allow for incorporation of time-
varying information on TAM adherence, use of inhibiting 
comedications, comorbidity and transition to postmeno-
pausal status, while modelling complex gene–gene inter-
actions without issues of sparse data or a reduction in 
power.42 ALPS also permits incorporation of prior biolog-
ical knowledge regarding the metabolic path of TAM, so 
that the search space for the algorithm is constrained to 
pathways consistent with currently understood biology.
The DBCG has a long history of contributions to the 
scientific community, informing clinical and treatment 
guidelines for breast cancer.26 30 44 It is thus an indispens-
able resource for addressing our study aims.
strengths And lImItAtIons
The current ProBe CaRe study is a large prospective 
cohort nested within a nearly complete source popu-
lation. The cohort has many strengths, including the 
completeness of high-quality data and a large represen-
tative study population from the Danish source popula-
tion. Our study design allows for thorough assessment of 
competing explanations for our findings, both through 
inclusion of a cohort of ER−/TAM− participants and an 
internal validation study to address possible errors in clas-
sification of key variables. It is the first cohort to examine 
reduced activity of TAM metabolism in premenopausal 
women with ample sample size. Moreover, all data 
(except for new laboratory data) were collected from 
standardised reports submitted to population-based 
prospective registries. In addition to DCBG data, we can 
link patient records to drug prescription, morbidity and 
mortality data from independently maintained registries 
to ensure that relevant covariates are considered.
One potential limitation of the ProBe CaRe cohort is 
the homogeneity of the study sample, as almost all patients 
are of European descent. However, there is no compa-
rable source with the same level of information quality 
to allow exploration of our aims in a more diverse study 
population. Lack of diversity is a potential limitation, but 
previous studies indicate that our findings may be extrap-
olated to external populations and can inform the future 
direction of research in more diverse populations.45–48
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Denmark. We welcome collaborations to enhance the 
utility of the data and biobank and will respond to all 
inquiries ( tlash@ emory. edu).
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